Navigation Links
HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference

an innovator in the development of new cell-based technologies," concluded Mr. Frank Menzler.

Recently, HepaLife's PICM-19 liver cell line for use in an artificial liver device significantly outperformed the world's most widely used human liver cell line, the HepG2-C3A. In tests designed to measure a crucial function of the liver, HepaLife's PICM-19 cells successfully synthesized 100% of the ammonia present, almost four times more than HepG2-C3A.

The same tests also demonstrated that PICM-19 cells are able to express high levels of cytochrome P-450 enzymes, a key liver-related function in the detoxification of drugs and xenobiotics. In contrast, HepG2-C3A showed very low or no detectable P450 activity at all.

(View HepaLife's April 10, 2007 press release and photographs: PICM-19 cells mimic liver's responses; significantly outperform most widely-used liver cell line: http://www.hepalife.com/20070410-1.html.php)

In previous weeks, HepaLife's proprietary bioreactor system, the main mechanical component of its patented bioartificial liver device, successfully replicated the liver's key function -- removal of toxic ammonia and synthesis of urea. Researchers consider this ability vital to successfully replicating the human liver's function in an artificial liver device.

(View HepaLife's April 30, 2007 press release: HepaLife achieves major milestone in development of artificial liver device: http://www.hepalife.com/20070430-1.html.php)

ABOUT HEPALIFE TECHNOLOGIES, INC.

HepaLife Technologies, Inc. (OTCBB: HPLF - News; FWB: HL1) (WKN: 500625) is a biotechnology company focused on the identification and development of cell-based technologies and products.

Current cell-based technologies under development by HepaLife include 1) the first-of-its-kind artificial liver device, 2) proprietary in-vitro toxicology and pre-clinical drug testing platforms, and 3) novel cell-culture based vaccine production to protect against t
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
2. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
3. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
4. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
5. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
6. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
7. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
8. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
9. Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetixs AAGP
10. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
11. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
Post Your Comments:
(Date:9/3/2008)...follow up results from chronically infected Hepati...e data obtained earlier in 2008, - Study is the ...-term antiviral effect of therapeutic Hepat...ngly support move into a second generation, vacci...ting through TLR act...
(Date:9/3/2008)..., Md., Sept. 3 /- Panacea Pharmaceuti...tent Number 7,413,737 covering,antibodies against ...H), a,proprietary human cancer biomarker and thera...collaboration with the Massachusetts Institute of,...ide rights to this patent,for development of human...
(Date:9/3/2008)...ses Operations, Updates Zingo Launch Progress and ...y Conference Call Today at 11:30 ...wswire-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ...e,operations to focus on commercial and late-stage...to a specialty pharmaceutical pain management,comp...
(Date:9/3/2008)...any, Sept. 3 /- A sub-analy...at treatment with prasugrel,compared with clopidog...rent heart attacks (7.4 percent vs. 9.7 percent, p...d around the time of an artery-opening,procedure k...or if they,occurred spontaneously during the longe...
Breaking Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 1Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 2Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 1Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 4Perrigo Announces Approval for Over the Counter Childrens Cetirizine Oral Solution 1763 1Perrigo Announces Approval for Over the Counter Childrens Cetirizine Oral Solution 1763 2Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 1Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 2Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 3Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 4
...007 - CytRx Corporation,(NASDAQ:CYTR), a biopharma...mmercialization of human therapeutics, today,annou... extension,of its completed Phase IIa clinical tri...linical trial was not placebo-controlled,arimoclo... be safe,and well-tolerated throughout the six-mon...
...ganon, the human,healthcare business unit of Akzo ... III clinical trials with corifollitropin alfa,(Or...e reached,their randomization target. , ,Corifoll...e. It is,the first of a new class of gonadotropins...h, due to its long half-life, one single,injection...
Other Medicine Technology:CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
(Date:9/4/2008)...RNewswire/ -- A groundbreaking program,dealing wit... status of,men, their shorter life spans, unmet ge... take place Wednesday, September 17 at White Plain...ers of the Westchester,medical and psychiatric soc....D. and Lionel Tiger, Ph.D., Dr. Legatto, an inte...
(Date:9/4/2008)...ol study, the presence of measles virus RNA was no...bances than in children with only GI disturbances....related to MMR vaccine timing. Study findings are... on September 4 ( http://dx.plos.org/10.1371/jour...n of measles vaccines in 1963, three to four milli...
(Date:9/4/2008)...in and pancreatic tumors , , THURSDAY, S...ing discoveries involving genetic mutations of two...nd pancreatic cancer -- may lead to new treatments...dies represent the most complete genetic analysis ...enetic map of these deadly cancers," Kenneth Kinzl...
(Date:9/4/2008)... are Sold-Out and Sustainable Packaging ...pt. 4 /PRNewswire/ -- The latest innovations in ra...s, and sustainable,packaging will be on full displ...September 9, 10, 11 at the Jacob K. Javits Convent...urals Pavilions at the event are sold-out and,sust...
Breaking Medicine News(10 mins):Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4Health News:HBA Exhibit Floor Offers Global Resources to the Beauty and Personal Care Industry 2Health News:HBA Exhibit Floor Offers Global Resources to the Beauty and Personal Care Industry 3
...an inquiry into four deaths allegedly due to power... circumstances leading to the deaths that occurred...ospital superintendent S.C. Tiwari told IANS. Ear...d denied the deaths were due to power cut, stating...
...lions of pounds that have gone into the NHS have b...ivitas here has been “little or no evidence of imp... worst in the developed world”. In addition it sa...creased in proportion to the vast sums ploughed in...
...Lusaka, Zambia, have explained that the programme ...rst two years.// The leaders made their report on...IDS Conference in Toronto. They explained that the... thought that it is simply not possible to provide...
...ing a pilot project in sterilisation of street dog...t their animal birth control (ABC) initiative acro...ions across Tamil Nadu and neighbouring states hav...t was successfully tried by the Chennai Corporatio...
Other Medicine News:Health News:The Aids Programme In Zambia Reported As A Success 2
Cruciate Retaining, Posterior Stabilized and Constrained Components.
...bilized knee has an advanced design which provides...surfacing and inset patellas. Precision machined c...fit with tibial articular surface and patella to r...rovide easy intraoperative change of sizes. Increa...
StelKast's Proven knee system is a long term, quality solution based on a clinically proven design. Available in both posterior stabilized and anatomically correct cruciate retaining configurations.
The Foundation Knee CR System was designed to replicate normal knee kinematics. The patello- femoral joint has a recessed, deepened and extended patella groove to minimize advancement of the patella,
Medicine Products: